SCHEMBL20022518

SCHEMBL20022518

CCOc1cn(CC2CCN(C)CC2)nc1C(=O)Nc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)cc1F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 6/20 0.53
AXL P30530 4/20 0.53
PDGFRA P16234 3/20 0.53
KIT P10721 2/20 0.53
FGFR2 P21802 1/20 0.53
MET P08581 14/20 0.52
SRC P12931 2/20 0.50
AURKA O14965 1/20 0.50
ABL1 P00519 1/20 0.50
LCK P06239 1/20 0.50
FER P16591 1/20 0.50
CDK8 P49336 1/20 0.50
TYRO3 Q06418 1/20 0.50
MERTK Q12866 1/20 0.50
MAP2K5 Q13163 1/20 0.50
AURKB Q96GD4 1/20 0.50
EGFR P00533 2/20 0.47
RET P07949 1/20 0.47
IGF1R P08069 1/20 0.47
MST1R Q04912 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20022515 0.93 KDR (0.51) KDRAXLPDGFRAKITFGFR2
SCHEMBL20022517 0.92 KDR (0.53) KDRAXLPDGFRAKITFGFR2
SCHEMBL20022521 0.90 MET (0.54) KDRAXLPDGFRAKITFGFR2
SCHEMBL20022512 0.88 MET (0.53) KDRAXLPDGFRAKITFGFR2
SCHEMBL20022510 0.86 MET (0.52) KDRAXLPDGFRAKITFGFR2
SCHEMBL20022519 0.85 KDR (0.53) KDRAXLPDGFRAKITFGFR2
SCHEMBL23458667 0.83 KDR (0.53) KDRAXLPDGFRAKITFGFR2
SCHEMBL20022513 0.82 KDR (0.54) KDRAXLPDGFRAKITFGFR2
SCHEMBL20022522 0.82 KDR (0.55) KDRAXLPDGFRAKITFGFR2
SCHEMBL23457122 0.82 KDR (0.51) KDRAXLPDGFRAKITFGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10934274-B2 Quinoline derivatives as TAM RTK inhibitors QURIENT CO., LTD. (KR) 2021-03-02 US disclosed
US-20180093968-A1 QUINOLINE DERIVATIVES AS TAM RTK INHIBITORS LEAD DISCOVERY CENTER GMBH (DE) 2018-04-05 US disclosed
US-20180093968-A1 QUINOLINE DERIVATIVES AS TAM RTK INHIBITORS LEAD DISCOVERY CENTER GMBH (DE) 2018-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10934274-B2 Quinoline derivatives as TAM RTK inhibitors TYRO3, MERTK, AXL KDR 19/4885AXL 3/4885PDGFRA 111/4885
US-20180093968-A1 QUINOLINE DERIVATIVES AS TAM RTK INHIBITORS TYRO3, MERTK, AXL KDR 19/4885AXL 3/4885PDGFRA 111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.